Efficacy of the C8 Nerve Root Block During Interscalene Block for Anesthesia of the Posterior Aspect of the Shoulder

August 8, 2019 updated by: JongHae Kim, Daegu Catholic University Medical Center

Efficacy of the 8th Cervical Nerve Root Block During Interscalene Brachial Plexus Block for Arthroscopic Shoulder Surgery: Prospective Randomized Controlled Study

This study evaluates the effects of selective 8th cervical nerve root block during interscalene brachial plexus block on the relief of pain intensity upon the introduction of a posterior portal during arthroscopic shoulder surgery. The 5th to 7th cervical nerve roots will be blocked in half of participants, while the 5th to 8th cervical nerve roots will be blocked in the other half.

Study Overview

Detailed Description

By blocking only the 5th to 7th cervical nerve blocks, conventional interscalene brachial plexus block spares the 8th cervical and 1st thoracic dermatomes which innervate the posterior aspect of the shoulder. To visualize the shoulder joint space during shoulder arthroscopic surgery, the introduction of a posterior portal is essential. However, conventional interscalene brachial plexus block cannot effectively relieve the pain caused by its insertion due to sparing of the 8th cervical and 1st thoracic dermatomes. The addition of the 8th cervical nerve root block to conventional interscalene brachial plexus block decreases pain intensity upon the introduction of a posterior portal.

Study Type

Interventional

Enrollment (Actual)

74

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Daegu, Korea, Republic of, 42472
        • Daegu Catholic University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 78 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • American Society of Anesthesiologists physical status 1 and 2
  • Arthroscopic shoulder surgery under interscalene brachial plexus block

Exclusion Criteria:

  • Patient refusal
  • Contralateral hemidiaphragmatic paralysis or paresis
  • Contralateral vocal cord palsy
  • Severe pulmonary restrictive disease
  • Coagulopathy
  • Allergy to local anesthetics or history of allergic shock
  • Difficulty communicating with medical personnel
  • Peripheral neuropathy or neurologic sequelae on the operative limb

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Interscalene block with C8 root block
The 5th to 8th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
Under ultrasound guidance, the 5th to 8th cervical nerve roots are blocked.
Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
Other Names:
  • Naropin
Active Comparator: Conventional interscalene block
The 5th to 7th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
Other Names:
  • Naropin
Under ultrasound guidance, the 5th to 7th cervical nerve roots are blocked.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain intensity upon the introduction of a posterior portal
Time Frame: 50 minutes after interscalene block
0, 1, and 2 represent no pain, mild pain, and severe pain, respectively.
50 minutes after interscalene block

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sensory blockade
Time Frame: 30 minutes after interscalene block
C5 to T1 dermatomal blockade graded from 0 to 2 (0 = no cold sensation, 1 = reduced cold sensation, and 2 = normal cold sensation) by applying ice to the shoulder
30 minutes after interscalene block
Motor blockade
Time Frame: 30 minutes after interscalene block
Motor blockade of the radial, ulnar, median, musculocutaneous, and axillary nerves graded from 0 to 2 (0 = complete block, 1 = partial block, and 2 = no block)
30 minutes after interscalene block
Ipsilateral hemidiaphragmatic blockade
Time Frame: Before interscalene block and 30 minutes after interscalene block
Extent of a reduction in the amplitude of excursion of the diaphragm on the vertical axis of the M-mode wave under M-mode ultrasound evaluation
Before interscalene block and 30 minutes after interscalene block
Horner's syndrome
Time Frame: Before interscalene block and 30 minutes after interscalene block
The extent of a reduction in the ipsilateral pupil size measured by a pupillometer Presence or absence of ptosis
Before interscalene block and 30 minutes after interscalene block
Pulmonary function test
Time Frame: Before interscalene block and 30 minutes after interscalene block
Forced expiratory volume at one second (FEV1) and FEV1/forced vital capacity before and 30 minutes after the end of local anesthetic injection
Before interscalene block and 30 minutes after interscalene block
Complications related with interscalene block
Time Frame: 24 hours
Presence or absence of vascular puncture, local anesthetic systemic toxicity, pneumothorax, and paresthesia
24 hours
Numerical pain rating score at admission to postanesthetic care unit
Time Frame: 5 minutes
Numerical pain rating score ranging from 0 to 10 (0 = no pain, 10 = worst pain imaginable) at admission to postanesthetic care unit
5 minutes
Numerical pain rating score at discharge from postanesthetic care unit
Time Frame: 30 minutes
Numerical pain rating score ranging from 0 to 10 (0 = no pain, 10 = worst pain imaginable) at discharge from postanesthetic care unit
30 minutes
Numerical pain rating score between 6 and 12 hours after surgery
Time Frame: 6 and 12 hours
Numerical pain rating score ranging from 0 to 10 (0 = no pain, 10 = worst pain imaginable) between 6 and 12 hours after surgery
6 and 12 hours
Numerical pain rating score 24 hours after surgery
Time Frame: 24 hours
Numerical pain rating score ranging from 0 to 10 (0 = no pain, 10 = worst pain imaginable) 24 hours after surgery
24 hours
Worst numerical pain rating score
Time Frame: 24 hours
Worst numerical pain rating score ranging from 0 to 10 (0 = no pain, 10 = worst pain imaginable) during 24 hours after surgery
24 hours
Postoperative hour when pain starts to be felt
Time Frame: 24 hours
Time at regression of anesthesia which starts to cause postoperative pain during 24 hours after surgery
24 hours
Patient's satisfaction about surgical anesthesia and postoperative analgesia
Time Frame: 24 hours
Likert scale consisting of "very dissatisfied", "dissatisfied", "unsure", "satisfied", and "very satisfied"
24 hours
Dose of postoperative analgesic use
Time Frame: 24 hours
Cumulative dose of analgesic required for postoperative analgesia during 24 hours after surgery
24 hours
Frequency of postoperative analgesic use
Time Frame: 24 hours
Frequency of analgesic use during 24 hours after surgery
24 hours
Dose of intraoperative analgesic use
Time Frame: 2 hours
Cumulative dose of analgesic to supplement incomplete surgical anesthesia
2 hours
Frequency of intraoperative analgesic use
Time Frame: 2 hours
Frequency of analgesic use to supplement incomplete surgical anesthesia
2 hours
Conversion into general anesthesia
Time Frame: 1 hour
Number of patients whose regional anesthesia is converted into general anesthesia due to incomplete surgical anesthesia provided by the regional anesthesia
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jong Hae Kim, MD, Daegu Catholic University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 4, 2018

Primary Completion (Actual)

August 8, 2019

Study Completion (Actual)

August 9, 2019

Study Registration Dates

First Submitted

March 22, 2018

First Submitted That Met QC Criteria

March 28, 2018

First Posted (Actual)

April 4, 2018

Study Record Updates

Last Update Posted (Actual)

August 12, 2019

Last Update Submitted That Met QC Criteria

August 8, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Shoulder Pain

Clinical Trials on Interscalene block with C8 root block

3
Subscribe